Tin tức & Cập nhật

Chỉ hiển thị Multimedia

Elobixibat bests prucalopride for functional constipation in head-to-head trial

16 Jul 2026 bởi

Elobixibat delivers superior symptom relief and quality-of-life improvements compared with prucalopride in the second-line treatment of patients with functional constipation, as shown in a head-to-head trial.

Elobixibat bests prucalopride for functional constipation in head-to-head trial

16 Jul 2026

Bile acid reductions with odevixibat tied to improved LFTs in patients with PFIC2

16 Jul 2026 bởi

In individuals receiving odevixibat for progressive familial intrahepatic cholestasis 2 (PFIC2), also known as bile salt export pump (BSEP) deficiency, reductions in serum bile acid (sBA) levels correlated with improvements in key liver function tests (LFTs), according to a post hoc subgroup analysis presented at ESPGHAN 2026.

Bile acid reductions with odevixibat tied to improved LFTs in patients with PFIC2

16 Jul 2026

Dupilumab shows therapeutic potential in eosinophilic gastritis

15 Jul 2026

In the treatment of patients with eosinophilic gastritis, the use of dupilumab helps improve histological outcomes, according to the proof-of-concept, phase II DEGAS study.

Dupilumab shows therapeutic potential in eosinophilic gastritis

15 Jul 2026

Patients with MASLD face heightened diabetes risk

14 Jul 2026 bởi

Metabolic dysfunction-associated steatotic liver disease (MASLD) carries an increased risk of type 2 diabetes (T2D), with the risk increase disproportionately higher for individuals with earlier-onset MASLD, as shown in a study.

Patients with MASLD face heightened diabetes risk

14 Jul 2026

Long-term dupilumab sustains symptom improvement in paediatric EoE

13 Jul 2026 bởi

Treatment with dupilumab for up to 100 weeks reduces the frequency and severity of symptoms in children with eosinophilic esophagitis (EoE), as measured by the validated Pediatric Eosinophilic Esophagitis Symptom Score version 2.0 (PEESSv2.0), according to results from the open-label extension of the phase III EoE KIDS study.

Long-term dupilumab sustains symptom improvement in paediatric EoE

13 Jul 2026

Ustekinumab Q4W dosing induces response, remission in children with moderate-to-severe UC

12 Jul 2026 bởi

Paediatric patients with moderately to severely active ulcerative colitis (UC) show a favourable response to ustekinumab administered once every 4 weeks (Q4W), according to a study. This results in greater clinical response and remission associated with higher serum drug levels.

Ustekinumab Q4W dosing induces response, remission in children with moderate-to-severe UC

12 Jul 2026

Link between protein type, mortality differs by sex, adiposity

10 Jul 2026

Sex, smoking status, and adiposity mediate the associations between dietary animal (AP) and plant proteins (PP) and mortality, reports a study.

Link between protein type, mortality differs by sex, adiposity

10 Jul 2026

Original New Drug Application Approvals by US FDA (16-30 June 2026)

09 Jul 2026

New drug applications approved by US FDA as of 16-30 June 2026 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (16-30 June 2026)

09 Jul 2026

Hepatic steatosis increases non-calcified plaque burden

08 Jul 2026

Hepatic steatosis may raise the risk of major adverse cardiovascular events through increased non-calcified plaque burden, according to a study.

Hepatic steatosis increases non-calcified plaque burden

08 Jul 2026

Dysphagia a red flag for poor outcomes after cardiovascular procedures

08 Jul 2026 bởi

Among individuals undergoing common cardiovascular procedures, those with a preoperative diagnosis of dysphagia face an increased risk of postoperative mortality and complications, according to a retrospective study.

Dysphagia a red flag for poor outcomes after cardiovascular procedures

08 Jul 2026

Tin tức & Cập nhật

Xem bài viết Tiêu hóa

Xem

Chuyên ngành:

Elobixibat bests prucalopride for functional constipation in head-to-head trial

Elobixibat bests prucalopride for functional constipation in head-to-head trial

Bile acid reductions with odevixibat tied to improved LFTs in patients with PFIC2

Bile acid reductions with odevixibat tied to improved LFTs in patients with PFIC2

Dupilumab shows therapeutic potential in eosinophilic gastritis

Dupilumab shows therapeutic potential in eosinophilic gastritis

Patients with MASLD face heightened diabetes risk

Patients with MASLD face heightened diabetes risk

Long-term dupilumab sustains symptom improvement in paediatric EoE

Long-term dupilumab sustains symptom improvement in paediatric EoE

Ustekinumab Q4W dosing induces response, remission in children with moderate-to-severe UC

Ustekinumab Q4W dosing induces response, remission in children with moderate-to-severe UC

Link between protein type, mortality differs by sex, adiposity

Link between protein type, mortality differs by sex, adiposity

Original New Drug Application Approvals by US FDA (16-30 June 2026)

Original New Drug Application Approvals by US FDA (16-30 June 2026)

Hepatic steatosis increases non-calcified plaque burden

Hepatic steatosis increases non-calcified plaque burden

Dysphagia a red flag for poor outcomes after cardiovascular procedures

Dysphagia a red flag for poor outcomes after cardiovascular procedures